Letters to the Editor

A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas

Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Seoul National University Cancer Research Institute, Seoul
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam
Department of Pathology, Seoul National University Hospital, Seoul
Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Seoul National University Cancer Research Institute, Seoul
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam
Seoul National University Cancer Research Institute, Seoul, Republic of Korea; Department of Pathology, Seoul National University Hospital, Seoul
Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Seoul National University Cancer Research Institute, Seoul
Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Seoul National University Cancer Research Institute, Seoul
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam
Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Seoul National University Cancer Research Institute, Seoul
Haematologica Early view Apr 1, 2021 https://doi.org/10.3324/haematol.2021.278301